{"id":69150,"date":"2026-07-01T12:00:16","date_gmt":"2026-07-01T04:00:16","guid":{"rendered":"https:\/\/flcube.com\/?p=69150"},"modified":"2026-07-01T12:00:17","modified_gmt":"2026-07-01T04:00:17","slug":"sanofi-reports-positive-phase-3-baby-comet-results-for-nexviazyme-in-infantile-onset-pompe-disease-ert-shows-100-survival-and-ventilation-free-outcomes-at-52-weeks","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69150","title":{"rendered":"Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease \u2013 ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sanofi S.A.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>) announced today <strong>positive top-line results<\/strong> from the <strong>Baby-COMET Phase 3 study<\/strong> (NCT04910776), a single-arm, open-label clinical trial evaluating <strong>Nexviazyme\u00ae (avalglucosidase alfa)<\/strong> in treatment-na\u00efve pediatric patients with <strong>infantile-onset Pompe disease (IOPD)<\/strong> aged six months and younger.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The study met its <strong>primary endpoint<\/strong>, demonstrating that <strong>100% of participants remained alive and free of invasive ventilation at 52 weeks<\/strong> of treatment. Additionally, the trial achieved <strong>all secondary endpoints<\/strong>, including survival and ventilation-free status at 12 and 18 months, along with numerical improvements across multiple disease progression metrics.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-overview\" class=\"wp-block-heading\">Clinical Trial Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Name<\/strong><\/td><td>Baby-COMET (NCT04910776)<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Single-arm, open-label, Phase 3<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>Treatment-na\u00efve pediatric patients \u22646 months with IOPD<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Proportion alive and free of invasive ventilation at 52 weeks<\/td><\/tr><tr><td><strong>Primary Result<\/strong><\/td><td><strong>100% success rate<\/strong> (statistically significant vs historical controls)<\/td><\/tr><tr><td><strong>Secondary Endpoints<\/strong><\/td><td>All met: 12-month and 18-month survival\/ventilation-free outcomes + disease progression metrics<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Consistent with established Nexviazyme profile; well tolerated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-disease-background-amp-unmet-need\" class=\"wp-block-heading\">Disease Background &amp; Unmet Need<\/h2>\n\n\n\n<h3 id=\"h-pompe-disease-spectrum\" class=\"wp-block-heading\">Pompe Disease Spectrum<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pathophysiology:<\/strong> Caused by <strong>deficient acid alpha-glucosidase (GAA) enzyme<\/strong> activity, leading to <strong>glycogen accumulation<\/strong> in muscle cells throughout the body<\/li>\n\n\n\n<li><strong>Infantile-Onset Pompe Disease (IOPD):<\/strong> Most severe form with <strong>rapid symptom progression<\/strong> beginning in infancy<\/li>\n\n\n\n<li><strong>Untreated prognosis:<\/strong> Heart failure and death within first year of life<\/li>\n\n\n\n<li><strong>Cardiac involvement:<\/strong> Hypertrophic cardiomyopathy, arrhythmias<\/li>\n\n\n\n<li><strong>Respiratory compromise:<\/strong> Progressive respiratory muscle weakness requiring invasive ventilation<\/li>\n\n\n\n<li><strong>Late-Onset Pompe Disease (LOPD):<\/strong> Progressive skeletal muscle deterioration over time<\/li>\n\n\n\n<li><strong>Mobility impact:<\/strong> Wheelchair dependence as disease advances<\/li>\n\n\n\n<li><strong>Respiratory decline:<\/strong> Mechanical ventilation often required for breathing support<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-historical-treatment-landscape\" class=\"wp-block-heading\">Historical Treatment Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Standard of Care:<\/strong> Myozyme\/Lumizyme (alglucosidase alfa) \u2013 first-generation enzyme replacement therapy (ERT)<\/li>\n\n\n\n<li><strong>Limitations:<\/strong> Suboptimal enzyme uptake due to limited mannose-6-phosphate (M6P) receptor binding affinity<\/li>\n\n\n\n<li><strong>Clinical Gap:<\/strong> Despite treatment, many IOPD patients still experience progressive disease and poor long-term outcomes<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-nexviazyme-next-generation-enzyme-replacement-therapy\" class=\"wp-block-heading\">Nexviazyme: Next-Generation Enzyme Replacement Therapy<\/h2>\n\n\n\n<h3 id=\"h-molecular-innovation\" class=\"wp-block-heading\">Molecular Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Enhanced Targeting:<\/strong> Engineered with <strong>approximately 15-fold higher M6P moieties<\/strong> compared to Myozyme\/Lumizyme<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> High-affinity binding to <strong>mannose-6-phosphate (M6P) receptors<\/strong> \u2013 the key pathway for cellular uptake and lysosomal delivery of ERT<\/li>\n\n\n\n<li><strong>Therapeutic Goal:<\/strong> Improve enzyme delivery to target tissues and enhance <strong>glycogen clearance<\/strong> in affected muscles<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-differentiation\" class=\"wp-block-heading\">Clinical Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Superior Uptake:<\/strong> Enhanced M6P receptor binding translates to more efficient cellular internalization<\/li>\n\n\n\n<li><strong>Tissue Penetration:<\/strong> Improved delivery to both cardiac and skeletal muscle compartments<\/li>\n\n\n\n<li><strong>Dosing Efficiency:<\/strong> Potential for better clinical outcomes at standard dosing regimens<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-implications\" class=\"wp-block-heading\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Orphan Drug Market:<\/strong> Pompe disease represents a <strong>high-value ultra-orphan indication<\/strong> with premium pricing dynamics<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Nexviazyme&#8217;s superior molecular design positions it as the <strong>preferred ERT for newly diagnosed IOPD patients<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Momentum:<\/strong> Positive Baby-COMET data supports <strong>label expansion<\/strong> and strengthens existing approvals across major markets<\/li>\n\n\n\n<li><strong>Commercial Trajectory:<\/strong> Sanofi expects accelerated adoption in the IOPD segment, building on Nexviazyme&#8217;s established presence in late-onset Pompe disease<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> IOPD indication could contribute <strong>USD 200\u2013300 million<\/strong> in incremental annual revenue given the critical unmet need and premium reimbursement environment<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-sanofi-s-rare-disease-portfolio-strategy\" class=\"wp-block-heading\">Sanofi&#8217;s Rare Disease Portfolio Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Franchise Leadership:<\/strong> Reinforces Sanofi&#8217;s position as a <strong>global leader in rare genetic disorders<\/strong><\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> Complements existing lysosomal storage disorder portfolio including Cerezyme, Fabrazyme, and Myozyme<\/li>\n\n\n\n<li><strong>Innovation Focus:<\/strong> Demonstrates commitment to <strong>next-generation biologics<\/strong> with enhanced targeting and efficacy profiles<\/li>\n\n\n\n<li><strong>Patient-Centric Approach:<\/strong> Addresses the most vulnerable patient population with potentially life-saving therapy<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory pathways, and commercial expectations. Actual outcomes may differ due to risks including final regulatory decisions, market dynamics, and competitive pressures.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><br><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi S.A. (NASDAQ: SNY) announced today positive top-line results from the Baby-COMET Phase 3 study&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69151,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[17,867,24,147],"class_list":["post-69150","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-nasdaq-sny","tag-rare-orphan-disease-drugs","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease \u2013 ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi S.A. (NASDAQ: SNY) announced today positive top-line results from the Baby-COMET Phase 3 study (NCT04910776), a single-arm, open-label clinical trial evaluating Nexviazyme\u00ae (avalglucosidase alfa) in treatment-na\u00efve pediatric patients with infantile-onset Pompe disease (IOPD) aged six months and younger.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69150\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease \u2013 ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks\" \/>\n<meta property=\"og:description\" content=\"Sanofi S.A. (NASDAQ: SNY) announced today positive top-line results from the Baby-COMET Phase 3 study (NCT04910776), a single-arm, open-label clinical trial evaluating Nexviazyme\u00ae (avalglucosidase alfa) in treatment-na\u00efve pediatric patients with infantile-onset Pompe disease (IOPD) aged six months and younger.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69150\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-01T04:00:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-01T04:00:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69150#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69150\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease \u2013 ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks\",\"datePublished\":\"2026-07-01T04:00:16+00:00\",\"dateModified\":\"2026-07-01T04:00:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69150\"},\"wordCount\":586,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69150#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0102.webp\",\"keywords\":[\"Clinical trial results\",\"NASDAQ: SNY\",\"Rare \\\/ orphan disease drugs\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69150#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69150\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69150\",\"name\":\"Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease \u2013 ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69150#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69150#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0102.webp\",\"datePublished\":\"2026-07-01T04:00:16+00:00\",\"dateModified\":\"2026-07-01T04:00:17+00:00\",\"description\":\"Sanofi S.A. (NASDAQ: SNY) announced today positive top-line results from the Baby-COMET Phase 3 study (NCT04910776), a single-arm, open-label clinical trial evaluating Nexviazyme\u00ae (avalglucosidase alfa) in treatment-na\u00efve pediatric patients with infantile-onset Pompe disease (IOPD) aged six months and younger.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69150#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69150\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69150#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0102.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease \u2013 ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69150#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease \u2013 ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease \u2013 ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks - Insight, China&#039;s Pharmaceutical Industry","description":"Sanofi S.A. (NASDAQ: SNY) announced today positive top-line results from the Baby-COMET Phase 3 study (NCT04910776), a single-arm, open-label clinical trial evaluating Nexviazyme\u00ae (avalglucosidase alfa) in treatment-na\u00efve pediatric patients with infantile-onset Pompe disease (IOPD) aged six months and younger.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69150","og_locale":"en_US","og_type":"article","og_title":"Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease \u2013 ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks","og_description":"Sanofi S.A. (NASDAQ: SNY) announced today positive top-line results from the Baby-COMET Phase 3 study (NCT04910776), a single-arm, open-label clinical trial evaluating Nexviazyme\u00ae (avalglucosidase alfa) in treatment-na\u00efve pediatric patients with infantile-onset Pompe disease (IOPD) aged six months and younger.","og_url":"https:\/\/flcube.com\/?p=69150","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-01T04:00:16+00:00","article_modified_time":"2026-07-01T04:00:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69150#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69150"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease \u2013 ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks","datePublished":"2026-07-01T04:00:16+00:00","dateModified":"2026-07-01T04:00:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69150"},"wordCount":586,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69150#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0102.webp","keywords":["Clinical trial results","NASDAQ: SNY","Rare \/ orphan disease drugs","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69150#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69150","url":"https:\/\/flcube.com\/?p=69150","name":"Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease \u2013 ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69150#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69150#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0102.webp","datePublished":"2026-07-01T04:00:16+00:00","dateModified":"2026-07-01T04:00:17+00:00","description":"Sanofi S.A. (NASDAQ: SNY) announced today positive top-line results from the Baby-COMET Phase 3 study (NCT04910776), a single-arm, open-label clinical trial evaluating Nexviazyme\u00ae (avalglucosidase alfa) in treatment-na\u00efve pediatric patients with infantile-onset Pompe disease (IOPD) aged six months and younger.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69150#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69150"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69150#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0102.webp","width":1080,"height":608,"caption":"Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease \u2013 ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69150#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease \u2013 ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0102.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69150"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69150\/revisions"}],"predecessor-version":[{"id":69152,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69150\/revisions\/69152"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69151"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}